Comments
Ranbaxy Laboratories on Friday posted a net loss of ₹73.65 crore for the quarter ended March 31.
The pharma major had recorded a net profit of ₹125.75 crore for the quarter ended March 31, 2013.
Ranbaxy’s net sales during the March quarter stood at ₹2,436.1 crore, rising by only 1.04 per cent from ₹2,411.1 crore in the same quarter of the previous fiscal. EPS stood at ₹1.73 against ₹2.97.
Arun Sawhney, Chief Executive Officer and Managing Director, said: “Despite multiple challenges, Ranbaxy met its sales guidance and continued to build on its strengths.
“At the same time, we continue to work closely with the regulatory agencies to address their concerns.”
“The company achieved its sales guidance of ₹13,000-13,500 crore for the 15-month period ended March 2014,” Ranbaxy said in a statement.
The company, which is moving to a fiscal year accounting method from the calendar year method, announced a net loss of ₹1,085.25 crore during the 15-month period from January 1, 2013, to March 31, 2014.
The company has been in regulatory concerns related to drug quality and faces sanctions from the US Food and Drugs Administration. Ranbaxy’s scrip fell by 1.26 per cent during the day to close at ₹463.60.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.